PD-1 checkpoint blockade is an emerging treatment for Merkel cell carcinoma

British Journal of Dermatology

Volumn 176, Issue 1, 2017, Pages 18-

  Cassler, N M ^a   Brownell, I ^b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

CANCER GROWTH; DISEASE COURSE; ENDOCRINE DISEASE; HUMAN; MERKEL CELL TUMOR; NOTE; OFF LABEL DRUG USE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RETREATMENT; TREATMENT RESPONSE; MERKEL CELL CARCINOMA; SKIN TUMOR;

ANTIGENS, CD274; CARCINOMA, MERKEL CELL; HUMANS; PROGRAMMED CELL DEATH 1 RECEPTOR; SKIN NEOPLASMS;

EID: 85010300533     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.14828     Document Type: Note

References (6)

1. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015; 33:1974–82.
2. Avelumab in subjects with Merkel cell carcinoma (JAVELIN Merkel 200). Available at: https://clinicaltrials.gov/ct2/show/NCT02155647 (accessed April 2016).
3. Pembrolizumab in treating patients with advanced Merkel cell cancer. Available at: https://clinicaltrials.gov/show/NCT02267603 (accessed April 2016).
4. Nghiem PT, Bhatia S, Lipson EJ et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med 2016; 374:2542–52.
5. Winkler JK, Bender C, Kratochwil C et al. PD-1 blockade: a therapeutic option for treatment of metastatic Merkel cell carcinoma. Br J Dermatol 2017; 176:216–19.
6. Patnaik A, Kang SP, Rasco D et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res 2015; 21:4286–93.